NCT03518320TERMINATEDanonymous

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Sponsor

Source record

Taris Biomedical LLC

Phase

Source record

Phase 1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Muscle-Invasive Bladder Cancer

Indication / condition

AI-normalized

Bladder Cancer TNM Staging Primary Tumor (T) T2

Intervention

Source record

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]

Source & freshness

Source record

NCT ID

NCT03518320

Original source

ClinicalTrials.gov

Source last updated

Aug 27, 2024

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03518320

Title

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Sponsor

Taris Biomedical LLC

Status

TERMINATED

Phase

Phase 1

Condition raw

Bladder Cancer TNM Staging Primary Tumor (T) T2

Condition normalized

Bladder Cancer TNM Staging Primary Tumor (T) T2

Modality raw

Bladder Cancer TNM Staging Primary Tumor (T) T2

Modality normalized

monoclonal antibody

Target raw

Muscle-Invasive Bladder Cancer

Target normalized

Muscle-Invasive Bladder Cancer

Interventions

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]

Public preview

Source record

The clinical trial investigated the safety and tolerability of TAR-200, a drug delivery system, in combination with Nivolumab for patients with muscle-invasive bladder cancer (MIBC) scheduled for radical cystectomy. The study was sponsored by Taris Biomedical LLC in collaboration with Bristol-Myers Squibb.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03518320

Status

TERMINATED

Phase

Phase 1

Sponsor

Taris Biomedical LLC

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 27, 2024

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03518320

Indication

Bladder Cancer TNM Staging Primary Tumor (T) T2

Modality

monoclonal antibody

Target

Muscle-Invasive Bladder Cancer

Intervention

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]

Source record